Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

por Tan, H, Gupta, P, Harness, J, Wolk, R, Chapel, S, Menter, A, Strober, B, Langley, RG, Krishnaswami, S, Papp, KA
Publicado 2013

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

por Hutmacher, MM, Papp, K, Krishnaswami, S, Ito, K, Tan, H, Wolk, R, Valdez, H, Mebus, C, Rottinghaus, ST, Gupta, P
Publicado 2017

Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis

por Checchio, T, Ahadieh, S, Gupta, P, Mandema, J, Puig, L, Wolk, R, Valdez, H, Tan, H, Krishnaswami, S, Tallman, A, Kaur, M, Ito, K
Publicado 2017

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials

por Strober, B.E., Gottlieb, A.B., van de Kerkhof, P.C.M., Puig, L., Bachelez, H., Chouela, E., Imafuku, S., Thaçi, D., Tan, H., Valdez, H., Gupta, P., Kaur, M., Frajzyngier, V., Wolk, R.
Publicado 2018